SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A decent increase of about 34.58% in the sales to Rs. 49328.80 millions was observed for the quarter ended June 2022. The sales figure stood at Rs. 36652.90 millions during the year-ago period.The Total Profit for the quarter ended June 2022 of Rs. 10118.00 millions grew from Rs.-1382.80 millionsOperating Profit saw a handsome growth to 14986.50 millions from 4550.30 millions in the quarter ended June 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 49328.80 36652.90 34.58 49328.80 36652.90 34.58 155859.80 141160.50 10.41
Other Income 1762.10 2116.90 -16.76 1762.10 2116.90 -16.76 11968.80 1920.70 523.15
PBIDT 14986.50 4550.30 229.35 14986.50 4550.30 229.35 38654.40 24490.80 57.83
Interest 870.70 1074.60 -18.97 870.70 1074.60 -18.97 3881.00 2675.20 45.07
PBDT 14115.80 1820.00 675.59 14115.80 1820.00 675.59 16568.10 20920.00 -20.80
Depreciation 3745.00 3069.30 22.01 3745.00 3069.30 22.01 13499.50 12364.30 9.18
PBT 10370.80 -1249.30 -930.13 10370.80 -1249.30 -930.13 3068.60 8555.70 -64.13
TAX 252.80 133.50 89.36 252.80 133.50 89.36 4068.50 131.70 2989.22
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 10118.00 -1382.80 -831.70 10118.00 -1382.80 -831.70 -999.90 8424.00 -111.87
Equity 2399.30 2399.30 0.00 2399.30 2399.30 0.00 2399.30 2399.30 0.00
PBIDTM(%) 30.38 12.41 144.72 30.38 12.41 144.72 24.80 17.35 42.95

Sun Pharma Inds. Share Price

1676.80 1.60 (0.10%)
20-Apr-2026 09:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1676.80
Dr. Reddys Lab 1236.95
Cipla 1237.00
Zydus Lifesciences 940.75
Lupin 2338.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×